Compare SELF & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | CELU |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 56.7M |
| IPO Year | N/A | N/A |
| Metric | SELF | CELU |
|---|---|---|
| Price | $5.02 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 27.5K | ★ 65.1K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | $12,733,279.00 | ★ $40,578,000.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | $76.00 |
| P/E Ratio | $31.13 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $1.00 |
| 52 Week High | $5.89 | $4.35 |
| Indicator | SELF | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 55.41 |
| Support Level | $5.03 | $1.62 |
| Resistance Level | $5.17 | $2.18 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 8.70 | 60.76 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.